Antianginal and cardiac metabolic effects of low-dose glucose infusion during pacing in patients with and without coronary artery disease.
Anginal threshold and cardiac metabolism during infusion of glucose, 350 mg/min, were compared with control values before, during, and after pacing in nine patients with coronary artery disease (CAD) and nine patients without coronary artery disease (non-CAD). Pacing induced no ischemia in non-CAD patients; in CAD patients, intolerable angina developed in less than 5 minutes. However, glucose infusion in the latter group increased the time to onset of angina (110 +/- 24 seconds before infusion versus 140 +/- 24 seconds following infusion) and decreased the extent of ST segment depression (1.8 +/- 0.3 mm before infusion versus 0.9 +/- 0.2 mm following infusion, p less than 0.01) following pacing. In all subjects, arterial levels and cardiac uptake of glucose rose by 100% (p less than 0.001) and those of free fatty acids fell by 50% (p less than 0.01). Arterial lactate and uptake of lactate by nonischemic myocardium increased by 30% (p less than 0.05). During pacing in CAD patients, this elevated uptake was outweighed by similar increases of lactate release from ischemic areas, leaving mean negative global exchanges unaltered. In CAD patients solely, rebuilding of cardiac glycogen after pacing was suggested from augmented citrate efflux in the control period but not during glucose infusion, suggesting a glycogen-sparing effect. Arterial concentrations and net cardiac fluxes of oxygen, glutamate, and alanine remained unaltered. In conclusion, beneficial effects of glucose during ischemia are associated with increased aerobic and anaerobic glycolysis, saving of glycogen, and decreased lipolysis.
Thomassen
A
A
Department of Cardiology, Skejby Sygehus, Aarhus N. Denmark.
Nielsen
T T
TT
Bagger
J P
JP
Henningsen
P
P
D000409:Alanine / Q000097:blood; D000787:Angina Pectoris / Q000378:metabolism / Q000517:prevention & control*; D001786:Blood Glucose / Q000032:analysis; D002304:Cardiac Pacing, Artificial; D002951:Citrates / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000378:metabolism* / Q000503:physiopathology; D004562:Electrocardiography; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005947:Glucose / Q000008:administration & dosage* / Q000378:metabolism; D005971:Glutamates / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood; D007773:Lactates / Q000097:blood; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism*; D010101:Oxygen Consumption / Q000187:drug effects
D001786:Blood Glucose; D002951:Citrates; D005230:Fatty Acids, Nonesterified; D005971:Glutamates; D007328:Insulin; D007773:Lactates; D005947:Glucose; D000409:Alanine